Skip to main content
SpringerLink
Log in

Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects

A Randomized, Open-Label, Crossover Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Background: Treatment with an oral antihyperglycaemic agent administered as monotherapy is often unsuccessful at achieving or maintaining glycaemic control in patients with type 2 diabetes mellitus. The combined use of sitagliptin and metformin is an effective treatment for type 2 diabetes mellitus, consistent with the complementary mechanisms of action by which these two agents improve glucose control.

Objectives: To establish bioequivalence between sitagliptin/metformin fixeddose combination (FDC) tablets (Janumet®) and co-administration of corresponding doses of sitagliptin and metformin as individual tablets.

Methods: This was an randomized, open-label, two-part, two-period crossover study, which included a total of 48 healthy subjects, 24 subjects per part (parts I and II). Within each part, subjects were assigned to receive treatments in random order; treatment periods were separated by a washout interval of at least 7 days. Eligible study participants included healthy, non-smoking (within previous 6 months), male and female subjects aged between 18 and 45 years with a body mass index ≤32kg/m2. Part I consisted of treatments A (co-administration of sitagliptin 50 mg and metformin 500 mg) and B (sitagliptin/metformin 50mg/500mg FDC tablet); part II consisted of treatments C (co-administration of sitagliptin 50 mg and metformin 1000 mg) and D (sitagliptin 50 mg/metformin 1000 mg FDC tablet). Blood samples were collected pre-dose and up to 72 hours post-dose in each treatment period for determination of plasma sitagliptin and metformin concentrations and calculation of the respective pharmacokinetic parameters.

The area under the plasma concentration-time curve from time zero to infinity (AUC∞) and the maximum plasma concentration (Cmax) for both sitagliptin and metformin were designated as the primary and secondary study endpoints, respectively, and analysed using an ANOVA model after logarithmic transformation of the data. Bioequivalence was established if the 90% confidence intervals (CIs) for the geometric mean ratios (GMRs; FDC tablet/co-administration) of the AUC∞ and Cmax for both sitagliptin and metformin fell within pre-specified bounds of (0.80, 1.25).

Results: The GMRs (90% CI) for the AUC∞ of sitagliptin 50 mg and metformin 500 mg were 0.98 (0.96, 1.00) and 1.0 (0.95, 1.04), respectively, and for Cmax of sitagliptin and metformin were 1.00 (0.94, 1.06) and 1.00 (0.94, 1.06), respectively. The GMRs (90% CI) for the AUC∞ of sitagliptin 50 mg and metformin 1000 mg (part II) were 0.97 (0.95, 0.99) and 1.00 (0.94, 1.07), respectively, and for the Cmax of sitagliptin and metformin were 0.94 (0.88, 1.01) and 1.01 (0.93, 1.10), respectively. In both part I and part II, the 90% CIs of the GMRs of the AUC∞ and Cmax for both sitagliptin and metformin all fell within the pre-specified bioequivalence bounds of (0.80, 1.25). Administration of single doses of sitagliptin/metformin 50 mg/500 mg (part I) and 50 mg/1000 mg FDC tablets (part II) and co-administration of corresponding doses of sitagliptin and metformin as individual tablets were generally well tolerated.

Conclusion: The sitagliptin/metformin 50 mg/500 mg and 50 mg/1000 mg FDC tablets are bioequivalent to co-administration of corresponding doses of sitagliptin and metformin as individual tablets and support bioequivalence to the sitagliptin/metformin 50 mg/850 mg tablet strength. These results indicate that the safety and efficacy profile of co-administration of sitagliptin and metformin can be extended to the sitagliptin/metformin FDC tablets.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Table II

Similar content being viewed by others

References

  1. DeFronzo RA. Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 1988; 37: 667–87

    CAS  PubMed  Google Scholar 

  2. Hundal RS, Krssak M, Dufour S, et al. Mechanism by which metformin reduces glucose production in type 2 diabetes. Diabetes 2000; 49: 2063–9

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Inzucchi SE, Maggs DG, Spollett GR, et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. N Engl J Med 1998; 338: 867–72

    Article  CAS  PubMed  Google Scholar 

  4. Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.JAMA 1999; 281: 2005–12

    Article  CAS  PubMed  Google Scholar 

  5. JANUVIA® (sitagliptin) tablets [product information]. Whitehouse Station (NJ): Merck & Co., Inc., 2007

  6. Holst JJ, Deacon CF. Inhibition of the activity of dipeptidylpeptidase IV as a treatment for type 2 diabetes. Diabetes 1998; 47: 1663–70

    Article  CAS  PubMed  Google Scholar 

  7. Deacon CF, Ahren B, Holst J. Inhibitors of dipeptidyl peptidase IV: a novel approach for the prevention and treatment of type 2 diabetes? Expert Opin Investig Drugs 2004; 13: 1091–102

    Article  CAS  PubMed  Google Scholar 

  8. Herman GA, Stevens C, Van Dyck K, et al. Pharmaco-kinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 2005; 78: 675–88

    Article  CAS  PubMed  Google Scholar 

  9. Bergman AJ, Stevens C, Zhou Y, et al. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 2006; 28: 55–72

    Article  CAS  PubMed  Google Scholar 

  10. Herman GA, Bergman A, Stevens C, et al. Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006; 91: 4612–9

    Article  CAS  PubMed  Google Scholar 

  11. Aschner P, Kipnes MS, Lunceford JK, et al. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care 2006; 29: 2632–7

    Article  CAS  PubMed  Google Scholar 

  12. Raz I, Hanefeld M, Xu L, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 2006; 49: 2564–71

    Article  CAS  PubMed  Google Scholar 

  13. Goldstein BJ, Feinglos MN, Lunceford JK, et al. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care 2007; 30: 1979–87

    Article  CAS  PubMed  Google Scholar 

  14. Nauck MA, Meininger G, Sheng D, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab 2007; 9: 194–205

    Article  CAS  PubMed  Google Scholar 

  15. Rosenstock J, Brazg R, Andryuk PJ, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2006; 28: 1556–68

    Article  CAS  PubMed  Google Scholar 

  16. Charbonnel B, Karasik A, Liu J, et al. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes inadequately controlled with metformin alone. Diabetes Care 2006; 29: 2638–43

    Article  CAS  PubMed  Google Scholar 

  17. Williams-Herman D, Johnson J, et al. Initial combination therapy with sitagliptin and metformin provides effective and durable glycemic control over 1 year in patients with type 2 diabetes: a pivotal phase III clinical trial. Diabetologia 2007; 50Suppl. 1: S52–3

    Google Scholar 

  18. Scott R, Loeys T, Davies MJ, et al. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab 2008; 10: 959–69

    Article  CAS  PubMed  Google Scholar 

  19. Raz I, Chen Y, Wu M, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin 2008; 24: 537–50

    Article  CAS  PubMed  Google Scholar 

  20. Brazg R, Xu L, Dalla MC, et al. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. Diabetes Obes Metab 2007; 9: 186–93

    Article  CAS  PubMed  Google Scholar 

  21. Williams-Herman D, Johnson J, Teng R, et al. Efficacy and safety of initial combination therapy with sitagliptin and metformin in patients with type 2 diabetes: a 54-week study. Curr Med Res Opin 2009; 25: 569–83

    Article  CAS  PubMed  Google Scholar 

  22. Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987; 15: 657–80

    Article  CAS  PubMed  Google Scholar 

  23. Food and Drug Administration. Bioavailability and bio-equivalence requirements; abbreviated applications; final rule. Fed Regist 2002; 67: 77668–75

    Google Scholar 

  24. JANUMET® (sitagliptin/metformin HCl) tablets [product information]. Whitehouse Station (NJ): Merck & Co., Inc., 2008

  25. Janumet (Sitagliptin/metformin). Formulary Journal 2007; 42: 282

    Google Scholar 

  26. Sitagliptin/metformin (Janumet) for type 2 diabetes. Med Lett Drugs Ther 2007; 49: 45-7

    Google Scholar 

  27. Dobs A, Goldstein BJ, Wieczorek L, et al. Triple combination therapy with sitagliptin, metformin, and rosiglitazone improves glycemic control in patients with type 2 diabetes. Diabetes 2008; 57Suppl. 1: A595–6

    Google Scholar 

  28. DeFronzo RA, Goodman AM. Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group. N Engl J Med 1995; 333: 541–9

    Article  CAS  PubMed  Google Scholar 

  29. Garber AJ, Duncan TG, Goodman AM, et al. Efficacy of metformin in type II diabetes: results of a double-blind, placebo-controlled, dose-response trial. Am J Med 1997; 103: 491–7

    Article  CAS  PubMed  Google Scholar 

  30. Migoya EM, Miller JL, Larson PJ, et al. Sitagliptin, a selective DPP-4 inhibitor, and metformin have complementary effects to increase active GLP-1 concentrations [abstract]. Diabetologia 2007; 50Suppl. 1: S52

    Google Scholar 

  31. Data on file, Bristol-Myers Squibb, Princeton (NJ): 2009

  32. Herman GA, Bergman A, Yi B, et al. Tolerability and pharmacokinetics of metformin and the dipeptidyl peptidase-4 inhibitor sitagliptin when co-administered in patients with type 2 diabetes. Curr Med Res Opin 2006; 22: 1939–47

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The funding for this study was provided by Merck Research Laboratories, Merck & Co., Inc. Elizabeth M. Migoya, Jutta L. Miller, Wei Zheng, Amy O. Johnson-Levonas, Qi Liu, Catherine Zhou Matthews, John A. Wagner and Keith M. Gottesdiener are employees or former employees of Merck & Co., Inc. and may own stock or hold stock options in the company. Wei Zheng is currently an employee of MedImmune, Inc., Gaithersburg, MD, USA. Qi Liu is currently an employee of the US FDA. The views expressed in this article are those of the authors and do not reflect official policy of the FDA. No official endorsement by the FDA is intended or should be inferred. The authors wish to thank the clinical site staff and subjects for their contributions to this study. In addition, Catherine Phillips and Kathleen Newcomb of Merck & Co., Inc. provided technical support in the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Merck & Co., Inc., RY34-A544, 126 East Lincoln Avenue, P.O. Box 2000, Rahway, New Jersey, 07065-0900, USA

    Elizabeth M. Migoya, Jutta L. Miller, Wei Zheng, Amy O. Johnson-Levonas, Qi Liu, Catherine Z. Matthews, John A. Wagner & Keith M. Gottesdiener

  2. Comprehensive Neuroscience, Inc., Miramar, Florida, USA

    Maria Gutierrez

Authors
  1. Elizabeth M. Migoya
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Jutta L. Miller
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Gutierrez
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Amy O. Johnson-Levonas
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Qi Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Catherine Z. Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John A. Wagner
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Keith M. Gottesdiener
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elizabeth M. Migoya.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Migoya, E.M., Miller, J.L., Gutierrez, M. et al. Bioequivalence of Sitagliptin/Metformin Fixed-Dose Combination Tablets and Concomitant Administration of Sitagliptin and Metformin in Healthy Adult Subjects. Clin. Drug Investig. 30, 855–866 (2010). https://doi.org/10.1007/BF03256914

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256914

Keywords

Search

Navigation